Advertisement
Canadian Journal of Cardiology

Ezetimibe-associated myopathy in monotherapy and in combination with a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor

      This paper is only available as a PDF. To read, Please Download here.
      Two cases of myopathy associated with ezetimibe are reported. In the first case, a woman on ezetimibe monotherapy presented with muscle pain and an elevated concentration of creatine kinase (CK) on two occasions, with ezetimibe 10 mg and with ezetimibe 5 mg after a washout period. The recurrence of muscle pain after washout and the CK increase both supported the hypothesis that ezetimibe alone can be linked to myalgia. In the second case, a man had been treated with atorvastatin, and ezetimibe 10 mg was added to improve his lipid profile. Two months later, the patient complained of muscle pain and a CK increase was noted. The appearance of symptoms when adding ezetimibe to atorvastatin supports a potential pharmacokinetic and/or a pharmacodynamic interaction between these two drugs. These cases suggest that ezetimibe monotherapy as well as ezetimibe associated with the use of a statin may induce myalgia. The mechanism by which ezetimibe could cause muscle pain is not known.
      Nous rapportons deux cas de myopathies associées à l’ézétimibe. Une femme se présente avec des douleurs musculaires et une élévation de la créatine kinase (CK) sous ézétimibe en monothérapie et ce en deux occasions : 1) avec ézétimibe 10 mg et, 2) avec ézétimibe 5 mg après une période sans traitement. La réapparition des douleurs musculaires après la période sans traitement et l’augmentation des CK appuient l’hypothèse selon laquelle l’ézétimibe seul pourrait causer des myalgies. Afin d’améliorer le profil lipidique d’un homme traité avec de l’atorvastatine, un traitement d’ézétimibe 10 mg fut ajouté. Deux mois plus tard, le sujet présente des douleurs musculaires associées à une augmentation des CK. L’apparition des symptômes à l’ajout de l’ézétimibe au traitement à l’aide d’atorvastatine soutient une interaction pharmacocinétique ou pharmacodynamique potentielle entre ces deux médicaments. Nos résultats indiquent que l’ézétimibe en monothérapie autant qu’en association avec des statines pourrait induire de la myalgie. Le mécanisme par lequel l’ézétimibe pourrait causer des douleurs musculaires n’est pas connu.

      Key Words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Canadian Journal of Cardiology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Hoerger T.J.
        • Bala M.V.
        • Bray J.W.
        • Wilcosky T.C.
        • LaRosa J.
        Treatment patterns and distribution of low-density lipoprotein cholesterol levels in treatment-eligible United States adults.
        Am J Cardiol. 1998; 82: 61-65
        • Xydakis A.M.
        • Ballantyne C.M.
        Combination therapy for combined dyslipidemia.
        Am J Cardiol. 2002; 90: 21K-29K
        • Kosoglou T.
        • Statkevich P.
        • Meyer I.
        • et al.
        Effects of ezetimibe on the pharmacodynamics and pharmacokinetics of lovastatin.
        Curr Med Res Opin. 2004; 20: 955-965
        • Feldman T.
        • Koren M.
        • Insull Jr, W.
        • et al.
        Treatment of high-risk patients with ezetimibe plus simvastatin co-administration versus simvastatin alone to attain National Cholesterol Education Program Adult Treatment Panel III low-density lipoprotein cholesterol goals.
        Am J Cardiol. 2004; 93: 1481-1486
        • Ballantyne C.M.
        • Blazing M.A.
        • King T.R.
        • Brady W.E.
        • Palmisano J.
        Efficacy and safety of ezetimibe co-administered with simvastatin compared with atorvastatin in adults with hypercholesterolemia.
        Am J Cardiol. 2004; 93: 1487-1494
        • Gagne C.
        • Bays H.E.
        • Weiss S.R.
        • et al.
        Efficacy and safety of ezetimibe added to ongoing statin therapy for treatment of patients with primary hypercholesterolemia.
        Am J Cardiol. 2002; 90: 1084-1091
        • van Heek M.
        • Farley C.
        • Compton D.
        • Hoos L.
        • Davis H.R.
        Ezetimibe selectively inhibits intestinal cholesterol absorption in rodents in the presence and absence of exocrine pancreatic function.
        Br J Pharmacol. 2001; 134: 409-417
        • van Heek M.
        • Farley C.
        • Compton D.
        • et al.
        Comparison of the activity and disposition of the novel cholesterol absorption inhibitor, SCH58235, and its glucuronide, SCH60663.
        Br J Pharmacol. 2000; 129: 1748-1754
        • Thompson P.D.
        • Clarkson P.
        • Karas R.H.
        Statin-associated myopathy.
        JAMA. 2003; 289: 1681-1690
        • Shek A.
        • Ferrill M.J.
        Statin-fibrate combination therapy.
        Ann Pharmacother. 2001; 35: 908-917
        • Reaven P.
        • Witztum J.L.
        Lovastatin, nicotinic acid, and rhabdomyolysis.
        Ann Intern Med. 1988; 109: 597-598
        • Norman D.J.
        • Illingworth D.R.
        • Munson J.
        • Hosenpud J.
        Myolysis and acute renal failure in a heart-transplant recipient receiving lovastatin.
        N Engl J Med. 1988; 318: 46-47
        • Fux R.
        • Morike K.
        • Gundel U.F.
        • Hartmann R.
        • Gleiter C.H.
        Ezetimibe and statin-associated myopathy.
        Ann Intern Med. 2004; 140: 671-672
        • Phillips P.S.
        • Haas R.H.
        • Bannykh S.
        • et al.
        Statin-associated myopathy with normal creatine kinase levels.
        Ann Intern Med. 2002; 137: 581-585
        • Phillips P.S.
        Ezetimibe and statin-associated myopathy.
        Ann Intern Med. 2004; 141: 649
        • Carroll J.E.
        • Brooke M.H.
        • DeVivo D.C.
        • Kaiser K.K.
        • Hagberg J.M.
        Biochemical and physiologic consequences of carnitine palmityltransferase deficiency.
        Muscle Nerve. 1978; 1: 103-110
        • Dulloo A.G.
        • Gubler M.
        • Montani J.P.
        • Seydoux J.
        • Solinas G.
        Substrate cycling between de novo lipogenesis and lipid oxidation: A thermogenic mechanism against skeletal muscle lipotoxicity and glucolipotoxicity.
        Int J Obes Relat Metab Disord. 2004; 28: S29-S37
        • Phillips P.S.
        • Phillips C.T.
        • Sullivan M.J.
        • Naviaux R.K.
        • Haas R.H.
        Statin myotoxicity is associated with changes in the cardiopulmonary function.
        Atherosclerosis. 2004; 177: 183-188
        • Simard C.
        • Turgeon J.
        The pharmacokinetics of ezetimibe.
        Can J Clin Pharmacol. 2003; 10: 13A-20A
        • Prueksaritanont T.
        • Zhao J.J.
        • Ma B.
        • et al.
        Mechanistic studies on metabolic interactions between gemfibrozil and statins.
        J Pharmacol Exp Ther. 2002; 301: 1042-1051
        • Ghosal A.
        • Hapangama N.
        • Yuan Y.
        • et al.
        Identification of human UDP-glucuronosyltransferase enzyme(s) responsible for the glucuronidation of ezetimibe (Zetia).
        Drug Metab Dispos. 2004; 32: 314-320
        • Prueksaritanont T.
        • Subramanian R.
        • Fang X.
        • et al.
        Glucuronidation of statins in animals and humans: A novel mechanism of statin lactonization.
        Drug Metab Dispos. 2002; 30: 505-512